{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:13:17Z","timestamp":1791097997757,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/mpa.0b013e31823cd9df","type":"journal-article","created":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T05:47:28Z","timestamp":1327556848000},"page":"759-766","source":"Crossref","is-referenced-by-count":59,"title":["Frequencies and Prognostic Role of KRAS and BRAF Mutations in Patients With Localized Pancreatic and Ampullary Adenocarcinomas"],"prefix":"10.1097","volume":"41","author":[{"given":"Nicolai Aagaard","family":"Schultz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Roslind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib J.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrid","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth N.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens","family":"Kruh\u00f8ffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Burcharth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"W\u00f8jdemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia S.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210212","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer.","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-16-20210212","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":". Cancer statistics, 2010.","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R3-16-20210212","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":". Pancreatic cancer.","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"key":"R4-16-20210212","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2006.09.2551","article-title":". Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.","volume":"25","author":"Sultana","year":"2007","journal-title":"J Clin Oncol"},{"key":"R5-16-20210212","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":". Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.","volume":"28","author":"Philip","year":"2010","journal-title":"J Clin Oncol"},{"key":"R6-16-20210212","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":". Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).","volume":"28","author":"Kindler","year":"2010","journal-title":"J Clin Oncol"},{"key":"R7-16-20210212","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s004230100232","article-title":"Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms.","volume":"386","author":"Esposito","year":"2001","journal-title":"Langenbecks Arch Surg"},{"key":"R8-16-20210212","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00534-004-0898-3","article-title":"Pathogenesis of carcinoma of the papilla of Vater.","volume":"11","author":"Fischer","year":"2004","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"R9-16-20210212","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.pathmechdis.3.121806.154305","article-title":"Pancreatic cancer.","volume":"3","author":"Maitra","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"R10-16-20210212","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1158\/1055-9965.EPI-08-0880","article-title":". Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies.","volume":"18","author":"Genkinger","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R11-16-20210212","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000123838","article-title":". Pancreatic carcinogenesis.","volume":"8","author":"Koorstra","year":"2008","journal-title":"Pancreatology"},{"key":"R12-16-20210212","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1055-9965.EPI-08-0630","article-title":". Genetic and epigenetic alterations of familial pancreatic cancers.","volume":"17","author":"Brune","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R13-16-20210212","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":". Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"R14-16-20210212","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjc.6605534","article-title":". Activating K-ras mutations outwith hotspot codons in sporadic colorectal tumoursimplications for personalised cancer medicine.","volume":"102","author":"Smith","year":"2010","journal-title":"Br J Cancer"},{"key":"R15-16-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.mpa.0000229010.62538.f2","article-title":". Pancreatic cancer: from bench to 5-year survival.","volume":"33","author":"Kleeff","year":"2006","journal-title":"Pancreas"},{"key":"R16-16-20210212","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years.","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"R17-16-20210212","first-page":"639","article-title":"Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis Trends Cell Biol.","volume":"14","author":"Repasky","year":"2004","journal-title":""},{"key":"R18-16-20210212","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":". Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R19-16-20210212","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/gut.2008.159137","article-title":". Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the RasRaf signalling pathway in advanced colorectal cancer.","volume":"58","author":"Seth","year":"2009","journal-title":"Gut"},{"key":"R20-16-20210212","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1200\/JCO.2009.22.4295","article-title":". KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.","volume":"27","author":"Richman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R21-16-20210212","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-09-1570","article-title":". KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.","volume":"15","author":"Ogino","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R22-16-20210212","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":". Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.","volume":"28","author":"Roth","year":"2010","journal-title":"J Clin Oncol"},{"key":"R23-16-20210212","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.","volume":"28","author":"Bardelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"R24-16-20210212","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000018737","article-title":". Molecular aspects of pancreatic cancer and future perspectives.","volume":"16","author":"Friess","year":"1999","journal-title":"Dig Surg"},{"key":"R25-16-20210212","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1038\/sj.onc.1205533","article-title":". Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers.","volume":"21","author":"Laghi","year":"2002","journal-title":"Oncogene"},{"key":"R26-16-20210212","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/0008-5472.CAN-06-3752","article-title":". K-ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.","volume":"67","author":"Campbell","year":"2007","journal-title":"Cancer Res"},{"key":"R27-16-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2353\/jmoldx.2008.070115","article-title":"Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.","volume":"10","author":"Feldmann","year":"2008","journal-title":"J Mol Diagn"},{"key":"R28-16-20210212","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/cncr.22559","article-title":". Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.","volume":"109","author":"Lee","year":"2007","journal-title":"Cancer"},{"key":"R29-16-20210212","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00428-006-0191-8","article-title":". Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.","volume":"448","author":"Immervoll","year":"2006","journal-title":"Virchows Arch"},{"key":"R30-16-20210212","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1158\/0008-5472.CAN-09-0015","article-title":". Genetic mutations associated with cigarette smoking in pancreatic cancer.","volume":"69","author":"Blackford","year":"2009","journal-title":"Cancer Res"},{"key":"R31-16-20210212","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/(SICI)1097-0142(19990815)86:4<596::AID-CNCR8>3.0.CO;2-H","article-title":". Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of vater.","volume":"86","author":"Matsubayashi","year":"1999","journal-title":"Cancer"},{"key":"R32-16-20210212","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/modpathol.3880270","article-title":". Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study.","volume":"14","author":"Agoff","year":"2001","journal-title":"Mod Pathol"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006676-201207000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:29:19Z","timestamp":1786048159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006676-201207000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e31823cd9df","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}